# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹3,621 Cr** H1 FY25 (+13%) * **PBT before Exceptional Items:** **₹225 Cr** Q2 (+34%) · **₹339 Cr** H1 (+22%) * **PAT before Exceptional Items:** **₹185 Cr** Q2 (+30%) · **₹339 Cr** H1 adj. (+18%) * **EBITDA before R&D:** **₹927 Cr** (+28%) | **26% margin** * **Net Working Capital:** **₹2,921 Cr** (Sep ’24) from ₹2,734 Cr (Mar ’24) ## B. Revenue Growth * **Broad-Based Momentum:** Top-line growth fueled by **all business segments**, with Entresto a key volume-driven contributor in Q2. * **Product Recovery:** Azithral shows signs of **stabilization and re-acceleration**, suggesting potential inflection in legacy product performance. ## C. Profit Margins * **Strong Margin Expansion:** EBITDA margin reached **26%**, driven by robust revenue growth, improved capacity utilization in OSD and API plants, and operating leverage from controlled fixed cost growth. * **Cost Discipline:** Fixed cost growth remained **below revenue growth**, while non-R&D expenses declined YoY, enhancing profitability. * **R&D Impact:** EBITDA after R&D settled at **17% of revenue**, reflecting continued investment in innovation. ## D. Balance Sheet * **Working Capital Intensity:** NWC increase reflects **higher operating intensity**, **new product launches**, and **recent facility ramp-ups**, supporting future growth. * **Debt Build-Up:** Net debt rise attributed to **working capital funding** and the **acquisition of Utility Therapeutics**, marking a strategic shift toward external growth. --- # 2. Product & Launch Performance ## A. Key Figures * **Products Launched:** **2** in India Branded · **3** in US market * **ANDA Approvals:** **226 total** (including **21 tentative**) * **ANDA Filings:** **269 cumulative** filings, with **6 approvals and 1 tentative** secured this quarter ## B. US Generics * **Generic Insulin Performance:** Launch achieved **decent market uptake** and secured **meaningful accounts**, despite **intense competition** and **lower-than-expected pricing**. * **Volume Growth Drivers:** Strong quarterly performance fueled by **Entresto** and **three to four new launches**, supported by gradual ramp-up in existing products. ## C. Branded Launches * **First US Branded Entry:** Acquisition of **Utility Therapeutics** marks strategic entry into the US branded space with **Pivya**, a product targeting **3 crore annual prescriptions** in urinary tract infections. * **Launch Strategy:** Focused rollout planned for **late Q4 FY'26**, starting with a **small field force** targeting **high-prescription areas in women’s health**, to evaluate early traction before expansion. * **Commercial Buildout:** Field force will **ramp up gradually** as sales stabilize; company to simultaneously pursue **in-licensing opportunities** to build a broader women’s health franchise. * **Deal Structure:** Acquisition included **$4M upfront**, **$4M in milestone payments** (launch and revenue-based), and **profit-sharing** with sellers. ## D. Approval Activity * **Pipeline Momentum:** Quarter saw **2 new ANDA filings** and **7 total approvals/tentative approvals**, reinforcing robust regulatory execution. --- # 3. Segment & Geography Mix ## A. Key Figures * **India Branded Revenue:** **₹639 Cr** (QoQ, +5% YoY) * **US Business Growth:** **+21%** (QoQ) * **API Business Growth:** **+15%** (QoQ) * **ROW Markets Growth:** **+31%** (QoQ) * **ROW Generics CAGR:** **~20%** (7–10 years) ## B. India Business * **Resilient Core Growth:** Branded India business delivered moderate growth despite **temporary GST-related billing disruptions** and festival timing shifts impacting the Eastern zone. * **Segment Outperformance:** **Gynecology, Ophthalmology, and Animal Health** are key growth drivers, outpacing market trends and contributing disproportionately to revenue. * **Recovery Trajectory:** Management expects field force productivity gains to close the gap with market growth, with full impact anticipated from next fiscal year. ## C. US Business * **Strong Volume-Led Expansion:** US business achieved robust growth on higher volumes, though Q-o-Q gross margin softness emerged due to **unfavorable product mix** or short-term factors. * **Strategic Brand Building:** US branded portfolio is a mid- to long-term priority, with field force expansion underway to drive prescription uptake and commercial scale. ## D. ROW Markets * **Accelerated International Momentum:** Rest of World markets posted strong growth across formulations and API, reversing prior muted demand trends. * **High-Growth Base Effect:** Current quarter’s **30% growth** in ROW generics benefited from a low base last year due to supply constraints; full-year growth expected at **15–20%**. * **Regulated Market Focus:** 85% of ROW sales come from high-barrier regulated markets including Europe, Canada, Australia, and select emerging economies. ## E. API Performance * **Temporary Uptick, Not Structural Shift:** API growth rebounded after eight quarters of sluggishness, driven by **lower-base development shipments**—viewed as exceptional, not indicative of sustained recovery. --- # 4. Capacity & Utilization ## A. Plant Utilization * **Headline:** Margin expansion supported by improved utilization of underutilized injectable and onco facilities, driven by strong US market demand. * **Headline:** New injectable plant now contributing to **higher margins** despite prior unabsorbed overheads, with significant H1 utilization gains. * **Headline:** Injectable onco plants operating below target but poised for H2 improvement on **backended product approvals and launches**. ## B. OSD & API Plants * **Headline:** OSD and API facilities running at **optimal capacity utilization**, indicating efficient asset deployment. * **Headline:** F-4 plant retains **available headroom**, positioning it for future capacity expansion without major capex near term. --- # 5. R&D & Innovation ## A. Key Figures * R&D Expenses: **₹187 Cr** (YoY, +41%) · **Guidance: ₹600–650 Cr** for FY * **R&D as % of Revenue:** **~10%** (QoQ) · **Guided to moderate to ~8%** by year-end ## B. R&D Spending * **Elevated Investment with Discipline:** Sharp YoY R&D increase reflects strategic focus on high-value pipelines, though spending is expected to trend down to **8% above guidance** by year-end. * **US R&D Discipline Maintained:** US spend moderated from 12–14% to **8% of revenue**, with management confirming no plans to revert, citing margin and return constraints. ## C. Peptide Development * **Peptide Pipeline Advancing, But Not Immediate:** Dedicated lab established for peptides including semaglutide and GLP-1s; however, **semaglutide excluded from initial US/Canada launches**. * **Early Approvals Secured, Broader Rollout Pending:** One peptide product approved, but **GLP-1 approvals still in regulatory review**, with commercialization expected only after further clearance. ## D. Complex Generics * **Tirzepatide (Mounjaro) in Launch Vanguard:** Company expects to be among first movers in multiple markets, with **upcoming approvals anticipated in the next few months**. * **Complex Injectables Driving Spend:** Recent R&D cost surge attributed to tirzepatide batches and **development of complex injectables**, expected to yield **moderately impactful, low-competition launches**. ## E. Therapeutic Focus * **Strategic Allocation to High-Value Segments:** Increased R&D directed at **complex injectables, peptides, oral solids, and drug discovery**, prioritizing **First to File, Day 1, and NCE-1 opportunities**. * **Confidence in Women’s Health Asset:** Management cites **proven safety in pregnancy** and **established European commercial use** for UTIs/women’s health as key differentiators for pipeline molecule. --- # 6. Risks & Pricing Pressures ## A. Generic Erosion * **Strategic De-Risking:** Women’s health prioritized to counter pricing pressures and reduce reliance on commoditized generic segments. * **No Supply-Driven Gains:** Absence of one-off benefits due to well-supplied markets and **fair erosion**, limiting short-term revenue uplift opportunities. ## B. Launch Timing Risk * **Execution Skepticism:** Investor concerns raised over specialty segment entry, citing industry precedents of rollbacks and questioning sustainability of new product success. ## C. Margin Pressure * **Near-Term Profitability Impact:** Investments in Pivya and field force expansion will pressure margins in **FY26 and FY27**, particularly in **Q1 and Q2**, with recovery expected from **Q3 onward**. * **Umbrella-Shaped Revenue Curve:** Initial lag in returns from commercial rollout, reflecting delayed prescription ramp-up despite long-term potential in underpenetrated specialty market. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **15%–20%** full-year range (ROW generics) · **~10%** projected for API segment * **EBITDA Margin Target:** **18%–19%** in next year or two · **20%** targeted within a couple of years * **Gross Margin Guidance:** **70%–75%** annual range expected for full year * **Product Launches:** **4–5** products expected in Q3 · **4–5** in Q4 * Upfront Costs (US Specialty): $12 million milestone payments over time · minimal operational cost via gradual field force ramp-up ## B. Revenue Forecast * **Growth Moderation Expected:** H2 growth to moderate due to **high prior-year base**, though full-year growth remains within guided range. * **J-Curve Launch Impact:** Q1 FY27 to mark first full quarter of new product sales, with revenue expected to accelerate as prescriptions ramp. * **Near-Term Uncertainty:** Delayed GST-related orders flowed into October, but trajectory remains unconfirmed pending sales data. * **Market Alignment Ahead:** Represented market growth expected to catch up to overall market trends, reversing acute therapy underperformance. ## C. Margin Target * **Margin Roadmap Reaffirmed:** EBITDA margin target of **20%** remains on track despite quarterly volatility, supported by scale and operational leverage. * **Gross Margin Stability:** Full-year gross margins expected to stabilize within guided **70%–75%** range despite near-term fluctuations. ## D. Launch Timeline * **Pipeline Momentum:** 8–10 product launches expected in second half, with plant utilization set to improve post-approvals and commercialization. * **Sustainable US Performance:** Current US business performance seen as durable, contingent on **no major erosion in key products like Entresto**. ## E. Capex Plan * **Debt Reduction Path:** Net debt expected to decline in FY'27, driven by **new product launches** and **growth from new facilities**, excluding Pivya impact. * **Controlled Specialty Rollout:** US specialty business to be scaled gradually, with **field force onboarding minimized** and upfront costs limited to milestone payments.